Barclays’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.52M | Buy |
+44,000
| New | +$3.63M | ﹤0.01% | 2030 |
|
|
2025
Q1 | – | Sell |
-100,000
| Closed | -$7.4M | – | 5346 |
|
|
2024
Q4 | $7.4M | Sell |
100,000
-67,400
| -40% | -$4.72M | ﹤0.01% | 1816 |
|
|
2024
Q3 | $11M | Buy |
+167,400
| New | +$12.2M | ﹤0.01% | 1414 |
|
|
2020
Q4 | – | Sell |
-20,000
| Closed | -$1.6M | – | 4972 |
|
|
2020
Q3 | $1.6M | Buy |
+20,000
| New | +$1.56M | ﹤0.01% | 2291 |
|
|
2020
Q2 | – | Sell |
-52,800
| Closed | -$3.32M | – | 5743 |
|
|
2020
Q1 | $3.32M | Buy |
52,800
+8,100
| +18% | +$584K | ﹤0.01% | 1832 |
|
|
2019
Q4 | $3.48M | Buy |
44,700
+27,900
| +166% | +$2.18M | ﹤0.01% | 2405 |
|
|
2019
Q3 | $1.23M | Sell |
16,800
-15,600
| -48% | -$1.1M | ﹤0.01% | 3458 |
|
|
2019
Q2 | $2M | Sell |
32,400
-84,000
| -72% | -$5.08M | ﹤0.01% | 2921 |
|
|
2019
Q1 | $7.42M | Buy |
116,400
+36,900
| +46% | +$2.11M | 0.01% | 1409 |
|
|
2018
Q4 | $4.06M | Sell |
79,500
-8,400
| -10% | -$425K | ﹤0.01% | 1741 |
|
|
2018
Q3 | $5.1M | Buy |
87,900
+9,000
| +11% | +$440K | ﹤0.01% | 1799 |
|
|
2018
Q2 | $3.83M | Buy |
78,900
+12,000
| +18% | +$560K | ﹤0.01% | 1950 |
|
|
2018
Q1 | $3.11M | Sell |
66,900
-83,100
| -55% | -$3.61M | ﹤0.01% | 2027 |
|
|
2017
Q4 | $5.64M | Buy |
150,000
+15,600
| +12% | +$573K | ﹤0.01% | 1582 |
|
|
2017
Q3 | $4.9M | Buy |
134,400
+85,500
| +175% | +$3.26M | 0.01% | 1541 |
|
|
2017
Q2 | $1.93M | Buy |
48,900
+13,200
| +37% | +$482K | ﹤0.01% | 2281 |
|
|
2017
Q1 | $1.12M | Sell |
35,700
-58,500
| -62% | -$1.83M | ﹤0.01% | 2644 |
|
|
2016
Q4 | $2.94M | Buy |
94,200
+40,500
| +75% | +$1.31M | ﹤0.01% | 1805 |
|
|
2016
Q3 | $2.16M | Sell |
53,700
-82,800
| -61% | -$3.12M | ﹤0.01% | 1939 |
|
|
2016
Q2 | $4.54M | Buy |
136,500
+92,100
| +207% | +$3.15M | 0.01% | 1384 |
|
|
2016
Q1 | $1.3M | Buy |
44,400
+3,000
| +7% | +$82.8K | ﹤0.01% | 2309 |
|
|
2015
Q4 | $1.08M | Buy |
41,400
+2,400
| +6% | +$62.3K | ﹤0.01% | 2551 |
|
|
2015
Q3 | $923K | Sell |
39,000
-9,000
| -19% | -$217K | ﹤0.01% | 2788 |
|
|
2015
Q2 | $1.14M | Buy |
48,000
+15,600
| +48% | +$352K | ﹤0.01% | 2777 |
|
|
2015
Q1 | $767K | Sell |
32,400
-97,800
| -75% | -$2.19M | ﹤0.01% | 3210 |
|
|
2014
Q4 | $2.76M | Sell |
130,200
-11,400
| -8% | -$229K | ﹤0.01% | 2239 |
|
|
2014
Q3 | $2.41M | Buy |
141,600
+600
| +0.4% | +$9.47K | ﹤0.01% | 2507 |
|
|
2014
Q2 | $2M | Sell |
141,000
-90,600
| -39% | -$1.23M | ﹤0.01% | 2597 |
|
|
2014
Q1 | $2.86M | Sell |
231,600
-219,000
| -49% | -$2.53M | ﹤0.01% | 2203 |
|
|
2013
Q4 | $4.88M | Buy |
450,600
+203,400
| +82% | +$2.29M | 0.01% | 1849 |
|
|
2013
Q3 | $2.84M | Buy |
247,200
+46,800
| +23% | +$548K | ﹤0.01% | 2198 |
|
|
2013
Q2 | $2.24M | Buy |
+200,400
| New | +$2.37M | ﹤0.01% | 2431 |
|
Other funds holding EW
VCM
VPM
Barclays's EW Position: Q1 2026 in Review
Barclays increased its Edwards Lifesciences (EW) stake by 3.2% in Q1 2026, buying an estimated $2.75M and bringing the position to 1,078,481 shares worth $86.4M. The position accounts for 0.02% of the portfolio, ranked #543.
Barclays first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $252M in Q4 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Barclays held 1,078,481 shares of Edwards Lifesciences worth $86.4M as of Q1 2026.
- Barclays bought 33,366 Edwards Lifesciences shares in Q1 2026, an estimated $2.75M.
- Edwards Lifesciences made up 0.02% of Barclays's portfolio in Q1 2026, its #543 holding.
- Barclays first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
- Barclays's Edwards Lifesciences position peaked at $252M in Q4 2021.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.